Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV000220570 | SCV000277361 | likely benign | Hereditary cancer-predisposing syndrome | 2015-07-20 | criteria provided, single submitter | clinical testing | Co-occurence with mutation in same gene (phase unknown);In silico models in agreement (benign) |
Labcorp Genetics |
RCV000689877 | SCV000817547 | likely benign | Neurofibromatosis, type 1 | 2025-01-06 | criteria provided, single submitter | clinical testing | |
Sema4, |
RCV000220570 | SCV002528146 | likely benign | Hereditary cancer-predisposing syndrome | 2021-02-17 | criteria provided, single submitter | curation | |
Ambry Genetics | RCV004558553 | SCV005048569 | likely benign | Hereditary cancer-predisposing syndrome; Cardiovascular phenotype | 2019-04-18 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Fulgent Genetics, |
RCV005016601 | SCV005639990 | uncertain significance | Neurofibromatosis, familial spinal; Juvenile myelomonocytic leukemia; Neurofibromatosis, type 1; Neurofibromatosis-Noonan syndrome; Café-au-lait macules with pulmonary stenosis | 2023-12-27 | criteria provided, single submitter | clinical testing |